1. Pharmacological treatment of depression in women with breast cancer: a systematic review

   • Lærke Toftegård Andersen
   • Melissa Voigt Hansen
   • Ismail Gögenur

   Review 28 September 2013 Pages: 325 - 330

   

2. Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis

   • April A. N. Rose
   • Christine Elser
   • Pamela J. Goodwin

   Review 09 October 2013 Pages: 331 - 339

   

3. DHA is a more potent inhibitor of breast cancer metastasis to bone and related osteolysis than EPA

   • Md Mizanur Rahman
   • Jyothi Maria Veigas
   • Gabriel Fernandes

   Preclinical Study 24 September 2013 Pages: 341 - 352

   

4. Analysis of phyllodes tumor recurrence according to the histologic grade

   • Sewha Kim
   • Ji-Ye Kim
   • Ja Seung Koo

   Preclinical Study 24 September 2013 Pages: 353 - 363

   

5. The expression of redox proteins in phyllodes tumor

   • Sewha Kim
   • Do Hee Kim
   • Ja Seung Koo

   Preclinical study 26 September 2013 Pages: 365 - 374

   

6. Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer

   • Kyle R. Covington
   • Lauren Brusco
   • Suzanne A. W. Fuqua

   Preclinical Study 28 September 2013 Pages: 375 - 384

   

7. Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents

   • Ingar Seemann
   • Johannes A. M. te Poele
   • Fiona A. Stewart

   Preclinical study Open access 04 October 2013 Pages: 385 - 395

   

8. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53

   • Ondrej Kalous
   • Dylan Conklin
   • Richard S. Finn

   Preclinical Study 05 October 2013 Pages: 397 - 408

   

9. The molecular diversity of Luminal A breast tumors

   • Giovanni Ciriello
   • Rileen Sinha
   • Nikolaus Schultz

   Preclinical study Open access 06 October 2013 Pages: 409 - 420

   

10. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice

    • Kathryn J. Ruddy
    • Stephen D. Desantis
    • Harold J. Burstein

    Clinical Trial 24 September 2013 Pages: 421 - 427

    

11. Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma

    • Eleni Andreopoulou
    • Ivette S. Vigoda
    • Joseph A. Sparano

    Clinical Trial 26 September 2013 Pages: 429 - 435

12. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

    • Sara A. Hurvitz
    • Florence Dalenc
    • Fabrice André

    Clinical trial Open access 08 October 2013 Pages: 437 - 446

    

13. Genetic variants in microRNAs and breast cancer risk in African American and European American women

    • Song Yao
    • Kelly Graham
    • Hua Zhao

    Epidemiology 24 September 2013 Pages: 447 - 459

14. Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer

    • Hope S. Rugo
    • Adam M. Brufsky
    • Denise A. Yardley

    Epidemiology Open access 24 September 2013 Pages: 461 - 470

    

15. Clinical characteristics of breast cancer in patients with an NBS1 mutation

    • T. Huzarski
    • C. Cybulski
    • The Polish Breast Cancer Consortium

    Epidemiology 27 September 2013 Pages: 471 - 476

    

16. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers

    • Jun Sang Lee
    • Seho Park
    • Byeong-Woo Park

    Epidemiology 27 September 2013 Pages: 477 - 484

    

17. Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer

    • Ariadna Tibau
    • Marguerite Ennis
    • Pamela J. Goodwin

    Epidemiology 27 September 2013 Pages: 485 - 493

    

18. Multivitamin and mineral use and breast cancer mortality in older women with invasive breast cancer in the women’s health initiative

    • S. Wassertheil-Smoller
    • A. P. McGinn
    • C. Thomson

    Epidemiology 09 October 2013 Pages: 495 - 505

    

19. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

    • Dorien J. A. Lobbezoo
    • Roel J. W. van Kampen
    • Vivianne C. G. Tjan-Heijnen

    Epidemiology 09 October 2013 Pages: 507 - 514

    

20. Identification of two novel BRCA1-partner genes in the DNA double-strand break repair pathway

    • Chiara Guglielmi
    • Iacopo Cerri
    • Maria Adelaide Caligo

    Brief Report 09 October 2013 Pages: 515 - 522